SG11202107659SA - New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine - Google Patents

New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Info

Publication number
SG11202107659SA
SG11202107659SA SG11202107659SA SG11202107659SA SG11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA
Authority
SG
Singapore
Prior art keywords
treatment
diseases characterized
new recombinant
diamine oxidase
excess histamine
Prior art date
Application number
SG11202107659SA
Inventor
Thomas Böhm
Bernd Jilma
Nicole Borth
Elisabeth Gludovacz
Original Assignee
Univ Wien Med
Univ Wien Bodenkultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med, Univ Wien Bodenkultur filed Critical Univ Wien Med
Publication of SG11202107659SA publication Critical patent/SG11202107659SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y104/00Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022Diamine oxidase (1.4.3.22)
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20Sequence assembly
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10Design of libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Library & Information Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
SG11202107659SA 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine SG11202107659SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157932 2019-02-19
PCT/EP2020/054197 WO2020169577A1 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Publications (1)

Publication Number Publication Date
SG11202107659SA true SG11202107659SA (en) 2021-09-29

Family

ID=65493995

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107659SA SG11202107659SA (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Country Status (12)

Country Link
US (1) US20220145269A1 (en)
EP (1) EP3927817A1 (en)
JP (1) JP2022520862A (en)
KR (1) KR20210132650A (en)
AU (1) AU2020225319A1 (en)
BR (1) BR112021015865A2 (en)
CA (1) CA3130751A1 (en)
EA (1) EA202192305A1 (en)
IL (1) IL285452A (en)
MX (1) MX2021010050A (en)
SG (1) SG11202107659SA (en)
WO (1) WO2020169577A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
AU2021353004A1 (en) 2020-09-30 2023-04-13 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2023235897A2 (en) * 2022-06-03 2023-12-07 Oyster Point Pharma. Inc. Aav vector encoding diamine oxidase and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317067B1 (en) 2000-11-29 2003-05-26 Univ Roma HISTAMINAS OF VEGETABLE ORIGIN IN THE TREATMENT OF ESPECTIC ALLERGIC SHOCK AND ALLERGIC ASTHMA.
AT502098B8 (en) 2004-07-07 2007-06-15 Albert Dr Missbichler DIAMOND OXIDASE-CONTAINING COMPOSITION
DK2611454T3 (en) 2010-09-02 2015-06-29 Naturland Magyarország Termelö És Kereskedelmi Kft Orally usable preparation, containing vegetable origin histaminase resistant to pepsin and trypsin, and process for preparation thereof

Also Published As

Publication number Publication date
AU2020225319A1 (en) 2021-10-14
EA202192305A1 (en) 2021-12-08
CN113785052A (en) 2021-12-10
EP3927817A1 (en) 2021-12-29
JP2022520862A (en) 2022-04-01
MX2021010050A (en) 2021-09-21
CA3130751A1 (en) 2020-08-27
US20220145269A1 (en) 2022-05-12
BR112021015865A2 (en) 2021-10-05
IL285452A (en) 2021-09-30
WO2020169577A1 (en) 2020-08-27
KR20210132650A (en) 2021-11-04

Similar Documents

Publication Publication Date Title
IL285452A (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
IL288214A (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
HUE058931T2 (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
EP4009948A4 (en) Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
IL284414A (en) Methods and compositions for the treatment of fabry disease
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
IL288195A (en) Use of cannabidiol in the treatment of epileptic spasms
IL287280A (en) Compounds and methods for the treatment of ocular disorders
IL291735A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
IL289405A (en) Personalized treatment of ophthalmologic diseases
EP4034109A4 (en) Method and composition for the treatment of disease
IL284029A (en) Peptides for treatment and prevention of diabetes and associated disorders
EP4010075A4 (en) Methods for the treatment of apoc3-related diseases and disorders
PL3937948T3 (en) Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases
EP3955914A4 (en) Novel compounds and methods of use treating fructose-related disorders or diseases
EP3744347A4 (en) Composition for skin diseases treatment use
GB201805100D0 (en) Treatment of sarcopenic diseases
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
SG11202010034WA (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
GB2574747B (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
ZA202106250B (en) Therapeutic uses of dulaglutide
GB201909438D0 (en) Treatment of diseases